信达生物宣布其开发的苏立信®(阿达木单抗注射液)在澳门获批上市,成为当地备受关注的生物药之一。此前,信达生物多款产品已在多个国家和地区获批,多款产品也拟在拉丁美洲、东南亚等地注册申报。苏立信®此次在澳门上市,不仅扩大了其可及范围,也为类风湿性关节炎、强直性脊柱炎等免疫疾病患者提供了高效治疗选择。临床研究显示,苏立信®与修美乐®疗效和安全性相似,且具有卓越有效性、良好安全性、用法规范、可及性高等优势...
Source Link信达生物宣布其开发的苏立信®(阿达木单抗注射液)在澳门获批上市,成为当地备受关注的生物药之一。此前,信达生物多款产品已在多个国家和地区获批,多款产品也拟在拉丁美洲、东南亚等地注册申报。苏立信®此次在澳门上市,不仅扩大了其可及范围,也为类风湿性关节炎、强直性脊柱炎等免疫疾病患者提供了高效治疗选择。临床研究显示,苏立信®与修美乐®疗效和安全性相似,且具有卓越有效性、良好安全性、用法规范、可及性高等优势...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.